T-Knife (Group)

https://www.t-knife.com

LinkedIn: https://www.linkedin.com/company/t-knife

T-knife is a next-generation adoptive T-cell company utilizing its proprietary humanized T-cell receptor (HuTCR) mouse platform technology to treat solid tumors. It was founded as a spin-off from Max-Delbruck Center for Molecular Medicine with support of Charité University Hospital in Berlin in 2018. Ascenion GmbH, technology transfer partner of MDC and Charité, accompanied the scientists from the beginning, continuously expanded the patent base, supported the acquisition of pre-seed funding and the negotiation of collaboration and license agreements in coordination with MDC and Charité. T-knife ´s mission is to use its unique technology to bring highly effective and safe T-cell receptor- based therapeutics to market. Based on the unparalleled T-cell immunology expertise of its founders and the unique and proprietary HuTCR platform, the Company develops fully human TCRs which are expected to set new technology standards and to provide superior safety and efficacy. The Company has demonstrated pre-clinical proof-of-concept and its lead TCR has entered clinical development. In addition, T-knife has validated the platform for over 90 undisclosed cancer targets, with several follow-on drug candidates being already in preclinical development. The Company expects to bring three additional TCRs into the clinic by 2022. T-knife is executing a two-pronged corporate growth strategy: developing an internal pipeline of best- in-class therapeutics and in parallel, establishing external partnerships by out-licensing already patented TCRs and/or providing the Company’s HuTCR mouse for unbiased discovery of new epitopes. T-knife is backed by top tier investors Versant Ventures, RA Capital, Andera Partners, and Boehringer Ingelheim Venture Fund. *

	Start	2018-03-13 reorganised
	Today	T-Knife GmbH
	Predecessor	T-Knife UG (haftungsbeschränkt)
	Industry	T cell therapy
	Industry 2	HuTCR transgenic mouse platform (T-Knife)
	Person	Soloway, Thomas M. (P.) (Tom) (T-Knife 202101– CEO before Audentes Tx + Ascendis Pharma + Transcept Pharmaceuticals)
	Person 2	Mayweg, Alexander (Alex) (Versant Ventures 202003 promoted to Managing Director joined 2016)

	Region	Berlin
	Country	Germany
	Street	10 Robert-Rössle-Str.
	City	10405 Berlin
	Tel	+49-30-94892432
		Address record changed: 2021-08-02

Basic data	Employees	n. a.

		* Document for »About Section«: T-Knife GmbH. (8/6/20). "Press Release: T-Knife Completes € 66 Million Series A Financing to Develop Next-Generation T-Cell Therapies". Berlin.

		Record changed: 2024-06-07